Induction of TNBS Colitis in Mice

Frank Scheiffele1, Ivan J. Fuss1

1 National Institute of Allergy and Infectious Disease, NIH, Bethesda, Maryland
Publication Name:  Current Protocols in Immunology
Unit Number:  Unit 15.19
DOI:  10.1002/0471142735.im1519s49
Online Posting Date:  August, 2002
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

The animal model described in this unit is one of several that have been used to study the immunopathogenesis of inflammatory bowel disease. The model employs the use of 2,4,6‐trinitrobenzenesulfonic acid (TNBS), which induces severe colonic inflammation when administered intrarectally in SJL/J mice. The colitis which results from this procedure presents clinical and histopathological findings that resemble those seen in Crohn's disease. The unit describes the critical parameters needed for successful induction of TNBS‐colitis as well methods for monitoring and grading disease levels. A support protocol for isolating lamina propria mononuclear cells from mouse colons is also included.

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Basic Protocol 1: Induction and Evaluation of TNBS Colitis in Mice
  • Support Protocol 1: Isolation of Mouse Mesenteric Lymph Node Cells
  • Support Protocol 2: Isolation of Lamina Propria Mononuclear Cells (LPMCs) from Mouse Colons
  • Reagents and Solutions
  • Commentary
  • Literature Cited
  • Figures
  • Tables
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

Basic Protocol 1: Induction and Evaluation of TNBS Colitis in Mice

  Materials
  • 2,4,6‐trinitrobenzenesulfonic acid (TNBS; also called picrylsulfonic acid; Sigma)
  • 45% to 50% ethanol
  • Male 5‐ to 6‐week‐old mice of known weight (SJL/J preferred; Table 15.19.1)
  • Inhalable anesthetic (e.g., methoxyflurane, isoflurane, halothane)
  • Surgical lubricant (e.g., Surgilube; E. Fougera)
  • 3.5‐French 38‐cm, polyurethane catheter (Sherwood Medical)
  • 1‐ml disposable syringe
  • Additional reagents and equipment for administering inhaled anesthesia to mice (unit 1.4), fixing tissue in 10% PBS‐buffered formalin, and hematoxylin and eosin (H & E) staining (unit 12.8), immunohistochemistry (unit 21.4) and isolation of mesenteric lymph node cells (MLNCs; see protocol 2) lamina propria mononuclear cells (LPMCs; see protocol 3) from mouse colons.
    Table 5.9.1   MaterialsMouse Strain Susceptibility to TNBS‐Induced Colitis

    Strain Haplotype Classification
    ASW/Sn H‐25 Intermediate
    Balb/c H‐2d Susceptible
    C 3H/HeOU   H‐2K Intermediate
    C57/B6 H‐2b Resistant
    C57/B10 H‐2b Resistant
    DBA/2 H‐2d Resistant
    SJL H‐25 Highly susceptible

Support Protocol 1: Isolation of Mouse Mesenteric Lymph Node Cells

  Materials
  • 1 to 2 mice treated with TNBS (see protocol 1)
  • 69% ethanol in a squeeze bottle
  • Hanks' balanced salt solution (HBSS; appendix 2A) without Ca2+ and Mg2+
  • Surgical instruments, sterile: scissors, forceps, and scalpel or razor blade
  • 10‐cm petri dish
  • Syringe plunger
  • 40‐ and 100‐µm nylon cell strainer
  • 50‐ml conical tube
  • Additional reagents and equipment for counting cells ( appendix 3A)

Support Protocol 2: Isolation of Lamina Propria Mononuclear Cells (LPMCs) from Mouse Colons

  • Mice treated with TNBS (see protocol 1)
  • recipeHBSS/EDTA (see recipe)
  • Iscove's modified Dulbecco medium supplemented with 10% FBS (IMDM‐10; appendix 2A) and 50 µg/ml gentamicin
  • 4000 Mandl units (3 × 106 Wünsch units)/ml collagenase D (Roche) in HBSS
  • 1 mg/ml DNase I (Roche) in HBSS
  • 70% and 30% Percoll: 7 parts:3 parts or 3 parts:7 parts recipe100% Percoll (see recipe): 1 mM EDTA/PBS ( appendix 2A)
  • PBS ( appendix 2A), free of Ca2+ and Mg2+
  • 10% PBS buffered formalin (Fisher Scientific)
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

Literature Cited
   Berg, D.J., Davidson, N., Kuhn, R., Muller, W., Menon, S., Holland, G., Thompson‐Snipes, L., Leach, L.W., and Rennick, D. 1996. Enterocolitis and colon cancer in interleukin‐10‐deficient mice are associated with aberrant cytokine production and CD4+ Th1‐like responses. J. Clin. Invest. 98:1010‐1020.
   Breese, E., Braegger, C., Corrigan, C., Walker‐Smith, J., and MacDonald, T. 1993. Interleukin‐2 and interferon‐γ secreting T cells in normal and diseased human intestinal mucosa. Immunology 78:127‐131.
   Cong, Y., Brandwein, S., McCabe, R., et al. 1998. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitis C3H/HeJBir mice: Increased T helper cell type 1 response and ability to transfer disease. J. Exp. Med. 187:855‐864.
   Duchmann, R., Schmitt, E., Knolle, P., Meyer zum Buschenfelde, K.H., and Neurath, M. 1996. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin‐10 or antibodies to interleukin‐12. Eur J. Immunol. 26:934‐938.
   Ehrhardt, R.O., Ludviksson, B.R., Gray, B., Neurath, M., and Strober, W. 1997. Induction and prevention of colonic inflammation in IL‐2‐deficient mice. J. Immunol. 158:566‐573.
   Elson, C.O., Beagley, K.W., Sharmanov, A.T., Fujihashi, K., Kiyono, H., Tennyson, G.S., Cong, Y., Black, C.A., Ridwan, B.W., and McGhee, J.R. 1996. Hapten‐induced model of murine inflammatory bowel disease: Mucosa immune responses and protection by tolerance. J. Immunol. 157:2174‐2185.
   Fuss, I.J., Neurath, M.F., Boirivant, M., Klein, J., Strong, S., Fiochhi, C., and Strober, W. 1996. Disparate CD4+ lamina propria (LP) lymphocyte secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN‐gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL‐5. J. Immunol. 157:1261‐1270.
   Fuss, I., Marth, T., Neurath, N., Pearlstein, G., Jain, A., and Strober, W. 1999. Anti‐interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 117:1078‐1088.
   Hollander, G.A., Simpson, S.J., Mizoguchi, E., Nichogiannapoulou, A., She, J., Gutierrez‐Ramos, J.C., Bhan, A.K., Burakoff, S.J., Wang, B., and Terhorst, C. 1995. Severe colitis mice with aberrant thymic selection. Immunity 3:27‐38.
   Hornquist, C.E., Lu, X., Rogers‐Fani, P.M., Rudolph, U., Shappell, S., Birnbauer, L., and Harriman, G.R. 1997. G(alpha)i2‐deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1‐type cytokines. J. Immunol 158:1068‐1077.
   Kühn, R., Löhler, J., Rennick, D., Rajewsky, K., and Müller, W. 1993. Interleukin‐10‐deficient mice develop chronic enterocolitis. Cell 75:263‐274.
   Ludviksson, B., Ehrhardt, R., Fuss, I., and Strober, W. 1997a. Mucosal and thymic dysregulation. Role in human intestinal inflammation. Immunologist 5:202‐209.
   Ludviksson, B.R., Ehrhardt, R.O., and Strober, W. 1997b. TGF‐beta production regulates the development of the 2,4,6‐trinitrophenol conjugated keyhole limpet hemocyanin‐induced colonic inflammation in IL‐2‐deficient mice. J. Immunol. 159:3622‐3628.
   Mizoguchi, A., Mizoguchi, E., Chiba, C., Spiekermann, G.M., Tonegawa, S., Nagler‐Anderson, C., and Bhan, A.K. 1996. Cytokine imbalance and autoantibody production in T cell receptor‐α mutant mice with inflammatory bowel disease. J. Exp. Med. 183:847‐856.
   Mombaerts, P., Mizoguchi, E., Grusby, M.J., Glimcher, L.H., Bhan, A.K., and Tonegawa, S. 1993. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 75:274‐282.
   Monteleone, G., Biancone, L., Marasco, R., Marrone, G., Marasco, O., Luzza, F., and Pallone, F. 1997. Interleukin‐12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112:1169‐1178.
   Morris, G., Beck, P., Herridge, M., Depew, W., Szewczuk, M., and Wallace, J. 1989. Hapten‐induced model of colonic inflammation and ulceration in the rat colon. Gastroenterology 96:795‐803.
   Mullin, G.E., Maycon, Z.R., Brown‐Elwert, L., Cerchia, R., James, S.P., Katz, S., Weissman, G.S., McKinley, M.J., and Fisher, S.E. 1996. Inflammatory bowel disease mucosal biopsies have specialized lymphokine mRNA profiles. Inflam. Bowel Dis. 27:16‐26.
   Neurath, M.F., Fuss, I., Kelsall, B.L., Stuber, E., and Strober, W. 1995. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182:1281‐1290.
   Neurath, M.F., Fuss, I., Kelsall, B.L., Presky, D.H., Waegell, W., and Strober, W. 1996. Experimental granulomatous colitis in mice is abrogated by induction of TGF‐beta‐mediated oral tolerance. J. Exp. Med. 183:2605‐2616.
   Neurath, M., Fuss, I., Pasparks, M., Alexopoulou, S., Haralambous, S., Meyer zum Buschenfelde, H., Strober, W., and Kollias, G. 1997. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. J. Immunol. 27:1743‐1750.
   Neurath, M.F., Fuss, I., Pettersson, S., Schurmann, G., Herfarth, C., Meyer zum Buschenfelde, K.H., and Strober, W. 2001. Upregulation of the IL‐12/Stat‐4 pathway distinguishes Crohn's disease from ulcerative colitis. Submitted for publication.
   Parronchi, P., Romagni, P., Annunziato, F., Sampognaro, S., Becchio, A., Giannarini, L., Maggi, E., Pupilli, C., Tonelli, F., and Romagni, S. 1997. Type 1 T‐helper cell predominance and IL‐12 expression in the gut of patients with Crohn's disease. Am. J. Pathol. 150:823‐832.
   Powrie, F., Leach, M.W., Mauze, S., Menon, S., Caddle, L.B., and Coffman, R.L. 1994. Inhibition of Th1 responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45Rbhi CD4+ T cells. Immunity 1:553‐562.
   Rudolph, U., Finegold, M.J., Rich, S.S., Harriman, G.R., Srinivasan, Y., Brabet, P., Bradley, A., and Birnbauer, L. 1995. Gi2 alpha protein deficiency: A model of inflammatory bowel disease. J. Clin. Immunol. 15(supp):101S‐105S.
   Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A.C., and Horak, I. 1993. Ulcerative colitis‐like disease in mice with a disrupted interleukin‐2 gene. Cell 75:253‐261.
   Sartor, R. 1995. Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis, and experimental intestinal inflammation. In Inflammatory Bowel Disease 4th edition (J. Kirsner and R. Shorter eds.) pp. 96‐124. Williams and Wilkins, Baltimore.
   Sartor, R. 1997. The influence of normal microbial flora on the development of chronic mucosal inflammation. Res. Immunol. 148:567‐576.
   Sundberg, J.P., Elson, C.O., Bedigian, H., and Birkenmeier, E.H. 1994. Spontaneous heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterology 107:1726‐1735.
   Targan, S., Hanauer, S., van Deventer, S., Mayer, L., Present, D., Braakman, T., DeWoody, K., Schaible, T., and Rutgeerts, P. 1997. A short‐term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N. Engl. J. Med. 337:1029‐1035.
   Watanabe, M., Ueno, Y., Yajima, T., Okamoto, S., Hayashi, T., Yamazaki, M., Iwao, Y., Ishii, H.Y., Habu, S., Uehira, M., et al. 1998. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J. Exp. Med. 187:389‐402.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library